ID   TLBR-3
AC   CVCL_A1EZ
SY   TLBR 3; TLBR3; T-cell Lymphoma BReast-3
DR   DSMZ; ACC-906
DR   DSMZCellDive; ACC-906
DR   GEO; GSM2527951
DR   Wikidata; Q102114992
RX   PubMed=22791880;
RX   PubMed=28356514;
CC   Doubling time: 77 hours (PubMed=22791880); ~20-50 hours (DSMZ=ACC-906).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ=ACC-906
ST   Amelogenin: X
ST   CSF1PO: 8,12
ST   D13S317: 9,13
ST   D16S539: 11
ST   D18S51: 12,13
ST   D19S433: 13
ST   D21S11: 29,31.2
ST   D2S1338: 18,23
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 10
ST   D8S1179: 8
ST   FGA: 21,23
ST   Penta D: 11,12,13
ST   Penta E: 12,17
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 15,16
DI   NCIt; C37194; Anaplastic large cell lymphoma, ALK-negative
DI   ORDO; Orphanet_300903; ALK-negative anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-04-25; Version: 8
//
RX   PubMed=22791880; DOI=10.1158/1078-0432.CCR-12-0101;
RA   Lechner M.G., Megiel C., Church C.H., Angell T.E., Russell S.M.,
RA   Sevell R.B., Jang J.K., Brody G.S., Epstein A.L.;
RT   "Survival signals and targets for therapy in breast implant-associated
RT   ALK -- anaplastic large cell lymphoma.";
RL   Clin. Cancer Res. 18:4549-4559(2012).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114; PMCID=PMC5393253;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//